The biotech firm reported a wider-than-expected loss but revenue surged year-over-year, exceeding analyst forecasts.
ARS Pharmaceuticals posted a Q1 GAAP loss of $0.61 per share, missing estimates by $0.08. The wider-than-expected loss contrasts with revenue growth, which reached $22.68 million, up 184.6% from the same period last year and $0.56 million above forecasts.
The company’s cash position remains strong, with $201.0 million in cash, cash equivalents, and short-term investments as of March 31, 2026. Shares outstanding totaled 99,300,137, providing a stable capital structure amid ongoing operations.